Dual glucose-ketone tracker on the way for diabetes patients – DPA

Abbott Nutrition agreed to pay $670 million to resolve claims related to its preterm infant formulas, without admitting liability. The settlement includes a Missouri case where a jury awarded $495 million to a plaintiff. Abbott maintains its products are safe and supported by medical professionals. Separately, Abbott challenged competitor Kendamil's advertising claims, with NAD recommending Kendamil remove certain claims about nutritional benefits.

Abbott Laboratories (ABT) received FDA approval for its Libre Duo 10 Day sensor, which tracks glucose and ketone levels. The company's stock closed at $112.47, with mixed returns over different periods. Analysts suggest ABT is 5.6% undervalued, with a fair value of $119.13, citing innovation in high-margin segments. However, investors should monitor diagnostic pricing in China and potential litigation risks.

The Trump administration may add two FDA deputy commissioner roles. FDA approved first-of-kind treatments from Revolution Medicines (Rasonque for pancreatic cancer), Priovant Therapeutics (Lisraya for dermatomyositis), and Janssen Biotech (Imaavy for wAIHA). Abbott's Libre Duo 10 Day received de novo authorization for a dual glucose and ketone monitoring system. FDA issued alerts for Abiomed, Medtronic, and Boston Scientific devices, and recalls for Boston Scientific and AVID Medical products.

Abbott Laboratories (ABT) received FDA authorization for its Libre Duo 10 Day system, a wearable that monitors glucose and ketone levels. The U.S. launch is planned for later this year. Abbott projects $60.4 billion revenue and $9.5 billion earnings by 2029. The company faces litigation and other challenges, but the new device could strengthen its diabetes platform. Analysts' fair value estimates for ABT shares range from $119 to $152.

Abbott (NYSE:ABT) received FDA authorization for Libre Duo, the first wearable to monitor glucose and ketones. The company plans a U.S. launch in 2026, targeting 8 million users. Abbott's stock is down 11% year-to-date, while competitor Dexcom (NASDAQ:DXCM) is up 34%. Abbott trades at a forward P/E of 21x with a $120.20 analyst target. Reimbursement expansion could drive growth, according to CEO Robert Ford.

Abbott Laboratories (NYSE: ABT) received FDA De Novo authorization for Libre Duo, a wearable that monitors glucose and detects rising ketone levels. The company plans a U.S. launch in 2026. Abbott's stock is down 11.29% over the past year but up 9.2% over the past month. The FDA approval is a regulatory milestone but may not immediately impact revenue.